Eli Lilly and Incyte report atopic dermatitis data of baricitinib

Eli Lilly submitted a regulatory application of baricitinib in Europe for moderate to severe atopic dermatitis. Credit: Paul Sableman.



  • Eli Lilly, Incyte report Phase III atopic dermatitis data of baricitinib